Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Major new trans Tasman healthcare fund:

This article was originally published in Clinica

Executive Summary

A new venture capital fund of NZ$150m (US$110m) is seeking to invest in companies from a broad range of life science sectors, including medical devices. BioPacificVentures (www.lifescienceventures.co.nz) is a collaboration of New Zealand venture capital firms AgResearch and Direct Capital, and one Swiss firm iventages venture capital. Its cornerstone international investor is Nestle, and Wrightson for New Zealand. "Monies are available immediately", Dr Andrew Kelly, of Direct Capital, told Clinica. "However, our expectation is that investing the money will take several years. We have advised our investors to expect six years of investment followed by six years as the companies grow and mature."

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel